Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project ...

UiPath's share price has risen in recent months despite ongoing losses and slow growth. While market conditions are stable, there is still elevated deal scrutiny and longer sales cycles, particularly ...

UiPath helps companies automate tasks traditionally performed by human employees with software robots. The slower-growth company might be the safer bet in this frothy market. Figma (NYSE: FIG) and ...

UiPath Inc. raised its full-year revenue outlook after cruising past Wall Street’s expectations and swinging to a profit in its latest quarterly results, powered by momentum in its artificial ...

UiPath Inc.’s recent earnings beat and raise provides some evidence that thus far, generative artificial intelligence has not been dilutive for the company. As an early leader that is transforming ...

UiPath offers an AI-driven automation platform, targeting workflow efficiency and accessibility for a broad range of users. PATH is undervalued, trading at a forward P/E of 22, an 11% discount to the ...

Total revenue increased 6% compared to the prior year’s quarter. Annual recurring revenue totaled $1.69 billion as of April 30, up 12% year-over-year. The agentic automation company reported cash flow ...

UiPath, Inc. (NYSE:PATH) shares are trading higher Tuesday after the company announced a partnership with OpenAI to develop ChatGPT to integrate OpenAI frontier models with enterprise customer ...

UiPath has been bruised badly in recent years, but the latest quarter offers hope. As demand for agents and automation picks up, perhaps the Street-high price target of $17 is due for a hike. Are you ...